文献速递主动脉疾病

胸降主动脉瘤腔内修复的长期结果

Long-term results of endovascular repair for descending thoracic aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2017-08-26

单中心回顾性研究纳入192例符合器械适应证的胸降主动脉瘤TEVAR患者,随访平均69个月。30天/院内死亡率为4.7%,141个月时总体生存率45.7%、主动脉相关生存率96.2%,7.3%因内漏需再干预。

要点

  • 符合适应证的退行性胸降主动脉瘤TEVAR长期主动脉相关生存率优异(96.2%)。
  • 内漏相关再干预率低(7.3%),且均经腔内处理成功。
  • TEVAR应视为此类患者的首选治疗。

核心结论

  • 对无综合征的退行性胸降主动脉瘤行符合适应证的TEVAR,12年主动脉相关生存率优异(96.2%),持续免受破裂风险,内漏再干预率低(7.3%)。

研究设计与样本

  • 单中心回顾性研究,2005年3月至2016年4月共579例TEVAR中筛选192例(33.2%)符合器械适应证的胸降主动脉瘤患者。
  • 动脉瘤类型包括梭形106例(55.2%)、囊状80例(41.7%)、两者兼有6例(3.1%)。
  • 排除主动脉夹层、壁内血肿及涉及弓部或内脏分支的杂交手术(左颈动脉-锁骨下动脉搭桥除外)。

主要发现

  • 平均年龄71.1±10.4岁,干预时平均主动脉直径5.9±1.5 cm。
  • 30天和院内死亡率4.7%,卒中2.1%,需永久透析0.5%,永久性截瘫/轻截瘫0.5%。
  • 平均随访69±44个月(范围3-141个月),晚期死亡68例(35.4%),其中2例死于主动脉破裂。
  • 141个月(11.8年)总体生存率45.7%,主动脉相关生存率96.2%。
  • 14例(7.3%)因I型(10例)、II型(2例)、III型(2例)内漏需腔内再干预,均后续解决,无开放再干预。

关键数值与推荐

  • TEVAR适用于位于左锁骨下动脉远端、腹腔干近端的退行性胸降主动脉瘤,且符合器械说明书适应证。

临床怎么用

  • 对于符合条件的退行性胸降主动脉瘤患者,TEVAR可作为首选治疗方式。
  • 长期随访中需关注内漏及再干预,但主动脉相关生存获益显著。

局限性

  • 单中心回顾性研究,样本量有限(192例),随访时间不等(3-141个月)。
  • 仅纳入符合器械适应证的退行性动脉瘤,排除了夹层、壁内血肿及复杂杂交手术,结果不能外推至所有胸主动脉病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Since thoracic endovascular aortic repair (TEVAR) received U.S. Food and Drug Administration approval for the treatment of descending thoracic aneurysms in March 2005, excellent 30-day and midterm outcomes have been described. However, data on long-term outcomes are lacking with Medicare data suggesting that TEVAR has worse late survival compared with open descending repair. As such, the purpose of this study was to examine the long-term outcomes for on-label use of TEVAR for repair of descending thoracic aneurysms. METHODS: Of 579 patients undergoing TEVAR between March 2005 and April 2016 at a single referral center for aortic surgery, 192 (33.2%) were performed for a descending thoracic aneurysm indication in accordance with the device instructions for use, including 106 fusiform (55.2%), 80 saccular (41.7%), and 6 with both saccular and fusiform (3.1%) aneurysms. All aneurysms were located distal to the left subclavian artery and proximal to the celiac axis, and hybrid procedures including arch or visceral debranching were excluded with the exception of left carotid-subclavian artery bypass. Aortic dissection and intramural hematoma as indications for TEVAR were also excluded. Primary 30-day and in-hospital outcomes included mortality, stroke, need for new permanent dialysis, and permanent paraparesis or paraplegia. Primary long-term outcomes included survival and rate of reintervention secondary to endoleak. The Kaplan-Meier method was used to estimate long-term overall and aorta-specific survivals. RESULTS: The mean age was 71.1 ± 10.4 years. All aneurysms in this series were degenerative in nature and no patients with a connective tissue disorder were included. The mean aortic diameter was 5.9 ± 1.5 cm at time of intervention. Rates of 30-day and in-hospital mortality, stroke, permanent dialysis, and permanent paraparesis and paraplegia were 4.7%, 2.1%, 0.5%, and 0.5%, respectively. At a mean follow-up of 69 ± 44 months (range, 3-141 months), there were 68 late deaths (35.4%), two of which were due to aortic rupture. Overall and aorta-specific survivals at 141 months (11.8 years) were 45.7% and 96.2%, respectively. Endovascular reintervention was required in 14 patients (7.3%) owing to type I (n = 10), type II (n = 2), and type III (n = 2) endoleak, all of which subsequently resolved. No patient required open reintervention for any cause. CONCLUSIONS: Long-term (12-year) aorta-specific survival after on-label endovascular repair of degenerative descending thoracic aneurysms in nonsyndromic patients is excellent (96%) with sustained protection from rupture, and a low rate of reintervention owing to endoleak (7%). Endovascular repair should be considered the treatment of choice for this pathology.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ranney DN, Cox ML, Yerokun BA, et al. Long-term results of endovascular repair for descending thoracic aortic aneurysms. J Vasc Surg. 2017. PMID: 28847657. doi:10.1016/j.jvs.2017.06.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。